Difference between revisions of "User:Rebecca B. Riggins"

From OpenWetWare
Jump to: navigation, search
(22 intermediate revisions by the same user not shown)
Line 1: Line 1:
 
==Contact Info==
 
==Contact Info==
[[Image:OWWEmblem.png|thumb|right|Rebecca B. Riggins (an artistic interpretation)]]
+
[[Image:IMG_2480_crop.jpg|thumb|right|Rebecca B. Riggins]]
  
*Rebecca B. Riggins
+
*Rebecca B. Riggins, Ph.D.
 +
*Department of Oncology, Lombardi Comprehensive Cancer Center
 
*Georgetown University Medical Center
 
*Georgetown University Medical Center
*Address 1
+
*Washington, DC
*Address 2
 
*City, State, Country etc.
 
 
*[[Special:Emailuser/Rebecca B. Riggins|Email me through OpenWetWare]]
 
*[[Special:Emailuser/Rebecca B. Riggins|Email me through OpenWetWare]]
 
+
*[http://openwetware.org/wiki/Riggins_Lab Riggins Lab Wiki]
I work in the [[Your Lab]] at XYZ University. I learned about [[OpenWetWare]] from online searching and the blogosphere, and I've joined because add a lab site or notebook.
+
*[http://explore.georgetown.edu/people/rbr7/ Georgetown University profile]
 +
*[http://www.lablife.org/labs/1238 LabLife page]
 +
*[http://network.nature.com/people/becca/profile Nature Network profile]
  
 
==Education==
 
==Education==
 
<!--Include info about your educational background-->
 
<!--Include info about your educational background-->
* Year, PhD, Institute
+
* 2003, PhD, University of Virginia
* Year, MS, Institute
+
* 1998, BA, Hood College
* Year, BS, Institute
 
  
 
==Research interests==
 
==Research interests==
 
<!-- Feel free to add brief descriptions to your research interests as well -->
 
<!-- Feel free to add brief descriptions to your research interests as well -->
# Interest 1
+
# cellular and molecular mechanisms of hormone independence and therapeutic resistance in breast cancer
# Interest 2
+
# pathogenesis of invasive lobular breast carcinoma
# Interest 3
+
# interaction(s) between exposure to the endocrine disruptor Bisphenol A (BPA), obesity, and breast cancer risk
  
 
==Publications==
 
==Publications==
 
<!-- Replace the PubMed ID's ("pmid=#######") below with the PubMed ID's for your publications.  You can add or remove lines as needed -->
 
<!-- Replace the PubMed ID's ("pmid=#######") below with the PubMed ID's for your publications.  You can add or remove lines as needed -->
 
<biblio>
 
<biblio>
#Paper1 pmid=6947258
+
#Paper1 pmid=20576803
#Paper2 pmid=13718526
+
#Paper2 pmid=20400521
 +
#Paper3 pmid=20375112
 +
#Paper4 pmid=20154269
 +
#Paper5 pmid=20062536
 +
#Paper6 pmid=20054984
 +
#Paper7 pmid=19697121
 +
#Paper8 pmid=19609461
 +
#Paper9 pmid=19444933
 +
#Paper10 pmid=19112081
 +
#Paper11 pmid=18974135
 +
#Paper12 pmid=17660348
 +
#Paper13 pmid=17616674
 +
#Paper14 pmid=17498560
 +
#Paper15 pmid=17475399
 +
#Paper16 pmid=16849545
 +
#Paper17 pmid=16112269
 +
#Paper18 pmid=15878912
 +
#Paper19 pmid=15657351
 +
#Paper20 pmid=15613442
 +
#Paper21 pmid=15173018
 +
#Paper22 pmid=12740391
 +
#Paper23 pmid=12692262
 +
#Paper24 pmid=11607844 
 
// leave a comment about a paper here
 
// leave a comment about a paper here
#Book1 isbn=0879697164
+
 
 
</biblio>
 
</biblio>
  

Revision as of 09:45, 27 June 2010

Contact Info

Rebecca B. Riggins

Education

  • 2003, PhD, University of Virginia
  • 1998, BA, Hood College

Research interests

  1. cellular and molecular mechanisms of hormone independence and therapeutic resistance in breast cancer
  2. pathogenesis of invasive lobular breast carcinoma
  3. interaction(s) between exposure to the endocrine disruptor Bisphenol A (BPA), obesity, and breast cancer risk

Publications

  1. Riggins RB, Mazzotta MM, Maniya OZ, and Clarke R. Orphan nuclear receptors in breast cancer pathogenesis and therapeutic response. Endocr Relat Cancer. 2010 Sep;17(3):R213-31. DOI:10.1677/ERC-10-0058 | PubMed ID:20576803 | HubMed [Paper1]
  2. Broustas CG, Ross JS, Yang Q, Sheehan CE, Riggins R, Noone AM, Haddad BR, Seillier-Moiseiwitsch F, Kallakury BV, Haffty BG, Clarke R, and Kasid UN. The proapoptotic molecule BLID interacts with Bcl-XL and its downregulation in breast cancer correlates with poor disease-free and overall survival. Clin Cancer Res. 2010 Jun 1;16(11):2939-48. DOI:10.1158/1078-0432.CCR-09-2351 | PubMed ID:20400521 | HubMed [Paper2]
  3. Chen L, Xuan J, Riggins RB, Wang Y, Hoffman EP, and Clarke R. Multilevel support vector regression analysis to identify condition-specific regulatory networks. Bioinformatics. 2010 Jun 1;26(11):1416-22. DOI:10.1093/bioinformatics/btq144 | PubMed ID:20375112 | HubMed [Paper3]
  4. Nehra R, Riggins RB, Shajahan AN, Zwart A, Crawford AC, and Clarke R. BCL2 and CASP8 regulation by NF-kappaB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells. FASEB J. 2010 Jun;24(6):2040-55. DOI:10.1096/fj.09-138305 | PubMed ID:20154269 | HubMed [Paper4]
  5. Crawford AC, Riggins RB, Shajahan AN, Zwart A, and Clarke R. Co-inhibition of BCL-W and BCL2 restores antiestrogen sensitivity through BECN1 and promotes an autophagy-associated necrosis. PLoS One. 2010 Jan 6;5(1):e8604. DOI:10.1371/journal.pone.0008604 | PubMed ID:20062536 | HubMed [Paper5]
  6. Chen L, Xuan J, Wang Y, Hoffman EP, Riggins RB, and Clarke R. Identification of condition-specific regulatory modules through multi-level motif and mRNA expression analysis. Int J Comput Biol Drug Des. 2009;2(1):1-20. PubMed ID:20054984 | HubMed [Paper6]
  7. Cavalli LR, Riggins RB, Wang A, Clarke R, and Haddad BR. Frequent loss of heterozygosity at the interferon regulatory factor-1 gene locus in breast cancer. Breast Cancer Res Treat. 2010 May;121(1):227-31. DOI:10.1007/s10549-009-0509-8 | PubMed ID:19697121 | HubMed [Paper7]
  8. Shajahan AN, Riggins RB, and Clarke R. The role of X-box binding protein-1 in tumorigenicity. Drug News Perspect. 2009 Jun;22(5):241-6. DOI:10.1358/dnp.2009.22.5.1378631 | PubMed ID:19609461 | HubMed [Paper8]
  9. Clarke R, Shajahan AN, Riggins RB, Cho Y, Crawford A, Xuan J, Wang Y, Zwart A, Nehra R, and Liu MC. Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells. J Steroid Biochem Mol Biol. 2009 Mar;114(1-2):8-20. PubMed ID:19444933 | HubMed [Paper9]
  10. Zhang B, Li H, Riggins RB, Zhan M, Xuan J, Zhang Z, Hoffman EP, Clarke R, and Wang Y. Differential dependency network analysis to identify condition-specific topological changes in biological networks. Bioinformatics. 2009 Feb 15;25(4):526-32. DOI:10.1093/bioinformatics/btn660 | PubMed ID:19112081 | HubMed [Paper10]
  11. Riggins RB, Lan JP, Zhu Y, Klimach U, Zwart A, Cavalli LR, Haddad BR, Chen L, Gong T, Xuan J, Ethier SP, and Clarke R. ERRgamma mediates tamoxifen resistance in novel models of invasive lobular breast cancer. Cancer Res. 2008 Nov 1;68(21):8908-17. DOI:10.1158/0008-5472.CAN-08-2669 | PubMed ID:18974135 | HubMed [Paper11]
  12. Gomez BP, Riggins RB, Shajahan AN, Klimach U, Wang A, Crawford AC, Zhu Y, Zwart A, Wang M, and Clarke R. Human X-box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines. FASEB J. 2007 Dec;21(14):4013-27. DOI:10.1096/fj.06-7990com | PubMed ID:17660348 | HubMed [Paper12]
  13. Schrecengost RS, Riggins RB, Thomas KS, Guerrero MS, and Bouton AH. Breast cancer antiestrogen resistance-3 expression regulates breast cancer cell migration through promotion of p130Cas membrane localization and membrane ruffling. Cancer Res. 2007 Jul 1;67(13):6174-82. DOI:10.1158/0008-5472.CAN-06-3455 | PubMed ID:17616674 | HubMed [Paper13]
  14. Bouker KB, Skaar TC, Harburger DS, Riggins RB, Fernandez DR, Zwart A, and Clarke R. The A4396G polymorphism in interferon regulatory factor 1 is frequently expressed in breast cancer cell lines. Cancer Genet Cytogenet. 2007 May;175(1):61-4. DOI:10.1016/j.cancergencyto.2006.12.008 | PubMed ID:17498560 | HubMed [Paper14]
  15. Riggins RB, Schrecengost RS, Guerrero MS, and Bouton AH. Pathways to tamoxifen resistance. Cancer Lett. 2007 Oct 18;256(1):1-24. DOI:10.1016/j.canlet.2007.03.016 | PubMed ID:17475399 | HubMed [Paper15]
  16. Riggins RB, Thomas KS, Ta HQ, Wen J, Davis RJ, Schuh NR, Donelan SS, Owen KA, Gibson MA, Shupnik MA, Silva CM, Parsons SJ, Clarke R, and Bouton AH. Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b. Cancer Res. 2006 Jul 15;66(14):7007-15. DOI:10.1158/0008-5472.CAN-05-3952 | PubMed ID:16849545 | HubMed [Paper16]
  17. Riggins RB, Bouton AH, Liu MC, and Clarke R. Antiestrogens, aromatase inhibitors, and apoptosis in breast cancer. Vitam Horm. 2005;71:201-37. DOI:10.1016/S0083-6729(05)71007-4 | PubMed ID:16112269 | HubMed [Paper17]
  18. Bouker KB, Skaar TC, Riggins RB, Harburger DS, Fernandez DR, Zwart A, Wang A, and Clarke R. Interferon regulatory factor-1 (IRF-1) exhibits tumor suppressor activities in breast cancer associated with caspase activation and induction of apoptosis. Carcinogenesis. 2005 Sep;26(9):1527-35. DOI:10.1093/carcin/bgi113 | PubMed ID:15878912 | HubMed [Paper18]
  19. Riggins RB, Zwart A, Nehra R, and Clarke R. The nuclear factor kappa B inhibitor parthenolide restores ICI 182,780 (Faslodex; fulvestrant)-induced apoptosis in antiestrogen-resistant breast cancer cells. Mol Cancer Ther. 2005 Jan;4(1):33-41. PubMed ID:15657351 | HubMed [Paper19]
  20. Hilakivi-Clarke L, Wang C, Kalil M, Riggins R, and Pestell RG. Nutritional modulation of the cell cycle and breast cancer. Endocr Relat Cancer. 2004 Dec;11(4):603-22. DOI:10.1677/erc.1.00665 | PubMed ID:15613442 | HubMed [Paper20]
  21. Bouker KB, Skaar TC, Fernandez DR, O'Brien KA, Riggins RB, Cao D, and Clarke R. interferon regulatory factor-1 mediates the proapoptotic but not cell cycle arrest effects of the steroidal antiestrogen ICI 182,780 (faslodex, fulvestrant). Cancer Res. 2004 Jun 1;64(11):4030-9. DOI:10.1158/0008-5472.CAN-03-3602 | PubMed ID:15173018 | HubMed [Paper21]
  22. Riggins RB, Quilliam LA, and Bouton AH. Synergistic promotion of c-Src activation and cell migration by Cas and AND-34/BCAR3. J Biol Chem. 2003 Jul 25;278(30):28264-73. DOI:10.1074/jbc.M303535200 | PubMed ID:12740391 | HubMed [Paper22]
  23. Riggins RB, DeBerry RM, Toosarvandani MD, and Bouton AH. Src-dependent association of Cas and p85 phosphatidylinositol 3'-kinase in v-crk-transformed cells. Mol Cancer Res. 2003 Apr;1(6):428-37. PubMed ID:12692262 | HubMed [Paper23]
  24. Bouton AH, Riggins RB, and Bruce-Staskal PJ. Functions of the adapter protein Cas: signal convergence and the determination of cellular responses. Oncogene. 2001 Oct 1;20(44):6448-58. DOI:10.1038/sj.onc.1204785 | PubMed ID:11607844 | HubMed [Paper24]
    leave a comment about a paper here
All Medline abstracts: PubMed | HubMed

Useful links